Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Intangibles (2019 - 2025)

Vivos Therapeutics' Intangibles history spans 7 years, with the latest figure at $4.0 million for Q4 2025.

  • Quarterly results put Intangibles at $4.0 million for Q4 2025, up 889.0% from a year ago — trailing twelve months through Dec 2025 was $4.0 million (up 889.0% YoY), and the annual figure for FY2025 was $4.0 million, up 889.0%.
  • Intangibles for Q4 2025 was $4.0 million at Vivos Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $4.0 million in Q4 2025 to a low of $301690.0 in Q1 2021.
  • The 5-year median for Intangibles is $401500.0 (2024), against an average of $741189.4.
  • The sharpest move saw Intangibles dropped 21.94% in 2022, then surged 889.0% in 2025.
  • Year by year, Intangibles stood at $341000.0 in 2021, then dropped by 11.44% to $302000.0 in 2022, then surged by 39.07% to $420000.0 in 2023, then fell by 2.62% to $409000.0 in 2024, then surged by 889.0% to $4.0 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $4.0 million, $2.2 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.